Figure 3 | Scientific Reports

Figure 3

From: High throughput development of TCR-mimic antibody that targets survivin-2B80-88/HLA-A*A24 and its application in a bispecific T-cell engager

Figure 3

#21-3 detects endogenous SV2B80-88/HLA-A*24 expressed on human tumor cell lines. (a) HeLa/A02 or HeLa/A24 cells were labeled with #21-3 (0.1 µg/mL) or control mouse IgG for 30 min at 4 °C and were analyzed by FACS. The integrity of the peptide/HLA-A*24 expression was confirmed with an antibody against HLA-A*24. Representative FACS histograms are shown. (b) Jurkat/A24 cells were stained with #21-3 or control mouse IgG and were analyzed as described above. (c) The indicated human tumor cell lines were stained with #21-3 or control mouse IgG, and binding was determined as described above. (d) PBMC from HLA-A*24+ healthy donors were stained with #21-3. A representative gating strategy and #21-3 histogram compared with control mouse IgG are shown. All data are representative of two independent experiments.

Back to article page